Marika Colombo

Milan, 20156, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Erratum: Molecular determinants of response to PI3K/AKT/mTOR and KRAS pathways inhibitors in NSCLC cell lines.

Erratum: Molecular determinants of response to PI3K/AKT/mTOR and KRAS pathways inhibitors in NSCLC cell lines.

Journal: American journal of cancer research

Published: February 12, 2026

Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma.

Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma.

Journal: International journal of molecular sciences

Published: November 12, 2024

NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2).

NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2).

Journal: Cells

Published: October 31, 2022

LKB1: Can We Target an Hidden Target? Focus on NSCLC.

LKB1: Can We Target an Hidden Target? Focus on NSCLC.

Journal: Frontiers in oncology

Published: March 04, 2022

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 19, 2021

KRAS Targeting and Resistance: Anticipating the Expectable.

KRAS Targeting and Resistance: Anticipating the Expectable.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 10, 2021

Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines.

Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines.

Journal: American journal of cancer research

Published: September 25, 2020

LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.

LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 30, 2020

Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation.

Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation.

Journal: Cells

Published: February 17, 2020

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.

Journal: Frontiers in oncology

Published: February 03, 2020

LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.

LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 27, 2019

Showing 1-11 of 11

Last Updated: 09/26/2026